



#### Applications:

- Investigation of food borne illness.
- Monitoring of seafood for contamination.

- Detection of food poisons.

*Inventor:* Sherwood Hall (FDA).

*Relevant Publication:* EJ Schantz *et al.* Paralytic shellfish poison. VI. A procedure for the isolation and purification of the poison from toxic clam and mussel tissues. *J Am Chem Soc.* 1957 Oct;79(19):5230–5235, doi: 10.1021/ja01576a044.

*Patent Status:* HHS Reference No. E–278–2009/0—Research Tool. Patent protection is not being pursued for this technology.

*Licensing Status:* Available for licensing.

*Licensing Contact:* Michael A. Shmilovich, Esq.; 301–435–5019; [shmilovm@mail.nih.gov](mailto:shmilovm@mail.nih.gov).

#### Identification of Recent HIV–I Infection by Genotypic Analysis for Treatment Strategy

*Description of Technology:* This invention describes a bioinformatics algorithm capable of distinguishing between recently infected and chronically infected HIV–I patients based on the genetic diversity of HIV pro-pol sequences. Directly after infection with HIV–I, genetic diversity is extremely low. Previously, single genome sequencing was used to demonstrate that HIV–I genetic diversity accumulates after infection in a linear and predictable fashion during the first 8–10 months of infection (Kearney *et al.*, 2009). Using single genome sequencing, it is possible to determine whether a person had been infected with HIV–1 in the recent past. Single genome sequencing is, however, a research technique that is relatively labor intensive and somewhat expensive, making it less feasible for routine use. The invention improves on this analysis in both ease and cost, and is capable of estimating genetic diversity using a population-based sequence that is obtained by routine, commercially available genotyping through the determination of genotype sequence ambiguity, which resulted in both sensitive and specific identification of acute versus chronic infection. The algorithm is also capable of simultaneously determining drug resistance profiles, further representing significant improvement over current

antibody-based methods. Since recent data have shown that patients in the primary infection stage are estimated to be 26 times more infective than patients in the chronic stage of infection (Hollingsworth *et al.*, 2008), and epidemiological models of immediate antiretroviral therapy (ART) predict a shift from the endemic phase to the elimination phase within five years (Granich *et al.*, 2009), this invention represents a potentially valuable diagnostic tool for clinicians as well as an improvement over the current antibody-based methods of epidemiological research for determining HIV incidence.

#### Applications:

- HIV Diagnostics capable of distinguishing between a recent HIV infection and a chronic one. This feature will assist clinicians in the design of HIV treatment regimen and strategy.
- Analysis and prediction of patient's HIV drug resistance. Facilitating devising a treatment strategy.
- Epidemiological application due to ability of the test to report HIV incidence.

*Advantages:* The method offers important public health benefits with regards to HIV/AIDS as elaborated below:

- The method adds important value to conventional HIV genotyping and enhances the diagnostic usefulness of genotyping.
- The method offers an inexpensive and convenient way to distinguish recently infected from chronically infected subjects and thus provides important information regarding HIV drug management.
- The method can, simultaneously with the above, provide information regarding drug resistance mutations.
- The method is based on commercially available HIV–1 genotype sequence information and thus offers simplicity and convenience.
- The method can provide important and useful epidemiological information.

*Market:* A favorable market potential for the method exists, and it may in the future be routinely used in every clinical laboratory that provides genotyping services and by manufacturers and laboratories that provide tests for drug resistance patterns.

*Development Status:* Early stage.

*Inventors:* Frank Maldarelli *et al.* (NCI).

*Patent Status:* HHS Reference No. E–238–2009/0—Research Tool. Patent protection is not being pursued for this technology.

*Licensing Status:* Available for licensing.

*Licensing Contacts:* Uri Reichman, PhD, MBA, 301–435–4616, [UR7a@nih.gov](mailto:UR7a@nih.gov); John Stansberry, PhD, 301–435–5236, [js852e@nih.gov](mailto:js852e@nih.gov).

*Collaborative Research Opportunity:* The NCI HIV Drug Resistance Program, Host Virus Interaction Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact John D. Hewes, PhD at 301–435–3121 or [hewesj@mail.nih.gov](mailto:hewesj@mail.nih.gov) for more information.

Dated: September 9, 2009.

**Richard U. Rodriguez,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. E9–22223 Filed 9–14–09; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel Tachycardias and Arrhythmias.

*Date:* September 22, 2009.

*Time:* 11 a.m. to 1 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. (Telephone Conference Call).

*Contact Person:* Olga A. Tjurmina, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4138, MSC 7814 Bethesda, MD 20892. (301) 451–1375. [ot3d@nih.gov](mailto:ot3d@nih.gov).

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel Nucleosome Structure—Function.

*Date:* September 30–October 1, 2009.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Mark Hopkins Hotel, One Nob Hill, San Francisco, CA 94108.

*Contact Person:* Richard A. Currie, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1108, MSC 7890 Bethesda, MD 20892. (301) 435–1219. [currieri@csr.nih.gov](mailto:currieri@csr.nih.gov).

*Name of Committee:* Genes, Genomes, and Genetics Integrated Review Group Ethical, Legal, and Social Implications of Human Genetics Study Section.

*Date:* September 30, 2009.

*Time:* 11 a.m. to 4 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. (Telephone Conference Call).

*Contact Person:* Cheryl M. Corsaro, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2204, MSC 7890 Bethesda, MD 20892. (301) 435–1045. [corsaroc@csr.nih.gov](mailto:corsaroc@csr.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: September 3, 2009.

**Jennifer Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. E9–22006 Filed 9–14–09; 8:45 am]

BILLING CODE 4140–01–M

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Diabetes and Digestive and Kidney Diseases Initial Review Group; Digestive Diseases and Nutrition C Subcommittee.

*Date:* October 7–8, 2009.

*Open:* October 7, 2009, 8 a.m. to 8:30 a.m.

*Agenda:* To review procedures and discuss policy.

*Place:* The Fairmont Washington, DC, 2401 M Street, NW., Washington, DC 20037.

*Closed:* October 7, 2009, 8:30 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* The Fairmont Washington, DC, 2401 M Street, NW., Washington, DC 20037.

*Closed:* October 8, 2009, 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* The Fairmont Washington, DC, 2401 M Street, NW., Washington, DC 20037.

*Contact Person:* Dan E. Matsumoto, PhD, Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes Of Health, Room 749, 6707 Democracy Boulevard, Bethesda, MD 20892–5452, (301) 594–8894, [matsumotod@extra.niddk.nih.gov](mailto:matsumotod@extra.niddk.nih.gov).

*Name of Committee:* National Institute of Diabetes and Digestive and Kidney Diseases Initial Review Group; Diabetes, Endocrinology and Metabolic Diseases B Subcommittee.

*Date:* October 13–15, 2009.

*Open:* October 13, 2009, 5 p.m. to 5:30 p.m.

*Agenda:* To review procedures and discuss policy.

*Place:* Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

*Closed:* October 13, 2009, 5:30 p.m. to 9 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

*Closed:* October 14, 2009, 8 p.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

*Closed:* October 15, 2009, 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

*Contact Person:* John F. Connaughton, PhD, Chief, Chartered Committees Section, Review Branch, DEA, NIDDK, National Institutes Of Health, Room 753, 6707 Democracy Boulevard, Bethesda, MD 20892–5452, (301) 594–7797, [connaughtonj@extra.niddk.nih.gov](mailto:connaughtonj@extra.niddk.nih.gov).

*Name of Committee:* National Institute of Diabetes and Digestive and Kidney Diseases

Initial Review Group; Kidney, Urologic and Hematologic Diseases D Subcommittee.

*Date:* October 21–22, 2009.

*Open:* October 21, 2009, 8 a.m. to 8:30 a.m.

*Agenda:* To review procedures and discuss policy.

*Place:* Residence Inn Bethesda, 7335

Wisconsin Avenue, Bethesda, MD 20814.

*Closed:* October 21, 2009, 8:30 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications

*Place:* Residence Inn Bethesda, 7335

Wisconsin Avenue, Bethesda, MD 20814.

*Closed:* October 22, 2009, 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Residence Inn Bethesda, 7335

Wisconsin Avenue, Bethesda, MD 20814.

*Contact Person:* Barbara A. Woynarowska,

PhD, Scientific Review Administrator,

Review Branch, DEA, NIDDK, National

Institutes Of Health, Room 754, 6707

Democracy Boulevard, Bethesda, MD 20892–5452, (301) 402–7172,

[woynarowskab@niddk.nih.gov](mailto:woynarowskab@niddk.nih.gov).

(Catalogue of Federal Domestic Assistance

Program Nos. 93.847, Diabetes,

Endocrinology and Metabolic Research;

93.848, Digestive Diseases and Nutrition

Research; 93.849, Kidney Diseases, Urology

and Hematology Research, National Institutes of Health, HHS)

Dated: September 4, 2009.

**Jennifer Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. E9–22007 Filed 9–14–09; 8:45 am]

BILLING CODE 4140–01–M

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute on Deafness and Other Communication Disorders; Notice of Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Board of Scientific Counselors, NIDCD.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Institute on Deafness and